May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
UHR-OCT for Higher Definition of Early Retinal Changes After Intravitreal Bevacizumab (Avastin®) Application in Patients With AMD
F. Zeiler; C. Glittenberg; B. Povaay; B. Hermann; S. Lie; W. Drexler; S. Binder
Author Affiliations & Notes
  • F. Zeiler
    Dept of Ophthalmology, Rudolf Foundation Clinic, Vienna, Austria
    Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Austria
  • C. Glittenberg
    Dept of Ophthalmology, Rudolf Foundation Clinic, Vienna, Austria
    Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Austria
  • B. Povaay
    Biomedical Imaging Group, Department of Optometry & Vision Sciences, Cardiff University, Wales, Cardiff, United Kingdom
    Center for Biomedical Engineering and Physics, Medical University of Vienna, Vienna, Austria
  • B. Hermann
    Biomedical Imaging Group, Department of Optometry & Vision Sciences, Cardiff University, Wales, Cardiff, United Kingdom
    Center for Biomedical Engineering and Physics, Medical University of Vienna, Vienna, Austria
  • S. Lie
    Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Austria
  • W. Drexler
    Biomedical Imaging Group, Department of Optometry & Vision Sciences, Cardiff University, Wales, Cardiff, United Kingdom
    Center for Biomedical Engineering and Physics, Medical University of Vienna, Vienna, Austria
  • S. Binder
    Dept of Ophthalmology, Rudolf Foundation Clinic, Vienna, Austria
    Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Austria
  • Footnotes
    Commercial Relationships F. Zeiler, None; C. Glittenberg, None; B. Povaay, None; B. Hermann, None; S. Lie, None; W. Drexler, None; S. Binder, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3383. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      UHR-OCT for Higher Definition of Early Retinal Changes After Intravitreal Bevacizumab (Avastin®) Application in Patients With AMD
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      F. Zeiler, C. Glittenberg, B. Povaay, B. Hermann, S. Lie, W. Drexler, S. Binder; UHR-OCT for Higher Definition of Early Retinal Changes After Intravitreal Bevacizumab (Avastin®) Application in Patients With AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3383.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To investigate early structural changes of the Retinal/RPE/Choroicapillaris complex before and after intravitreal application of bevacizumab(Avastin®) in patients with AMD by comparison of standard Stratus OCT( Carl Zeiss Meditech) and UHR-OCT imaging systems.

Methods:: Six patients with neovascular AMD were examined with UHR-OCT and Stratus OCT one day before and 10-14 days after intravitreal application of 1.25mg (0.125ml) bevacizumab (Avastin®). UHR-OCT examinations were performed using a commercially available ultra-broad bandwidth (160 nm) Titanium:sapphire based femtosecond laser system with a high axial resolution of 3 µm and a transverse resolution of ~15 µm. Each data set produced a volume of 60 tomograms. Standard Stratus OCT(Carl Zeiss Meditec) images were performed simultaneously. Central Retinal Thickness(CRT) was measured with the retinal mapping programm of StratusOCT. For UHR-OCT a recently of our group developed measuring system was used. In addition to clinical examination BCVA testing was performed using EDTRS and Radner-charts.

Results:: 6 Patients,3 male and 3 female, age 74 to 86 years(average 78,8),2 right, 4 left eyes with active CNV or vascularised PED were included. CRT decreased significantly in 3 cases in Stratus OCT retinal mapping(min-128µm,max-519µm); average decrease of CRT was 132µm or 21.1% after injection. UHR-OCT measuring system showed a decrease of CRT in all cases(min-21µm,max-347µm), average decrease of CRT was 113µm or 15.1%. Effects of bevacizumab(Avastin®) on the single different layers could be shown with higher definition using UHR-OCT.In 3 cases residual fluid was only visible with UHR-OCT. Distance VA improved in 4 of 6 patients(min+6,max.+37 EDTRS letters), 2 patients showed stabilisation in distance VA(-1,-2 letters). All patients showed improvement of reading VA(min.+0.1 logRAD,max.+0.5 logRAD).

Conclusions:: Unprecedented resolution of the UHR-OCT provides more detailed information of early structural changes in the Retinal/RPE complex after intravitreal antiVEGF application. Better visualisation of the efficacy of new drugs will help in the decision of further treatment and follow up.

Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • imaging/image analysis: clinical • age-related macular degeneration 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept